The Power of Precision Medicine with Edith Perez, MD

In this episode, host Shikha Jain, MD, speaks with Edith Perez, MD, about equity initiatives in health care organizations, the evolution of precision oncology and more. Welcome to another exciting episode of Oncology Overdrive :14 About Perez :21 The interview 1:03 Tell me about yourself and how you got to where you are today 1:20 About Perez's involvement in many kinds of work in oncology 4:45 How did you get involved in your equity and philanthropy work, and what do you do? 5:44 Do you feel like your work has been changed or modified over the last couple of years with the pandemic, or did knowledge of the problem already exist? 8:30 What changes do you hope to see in the next 5 to 10 years? Long-term, what are the biggest issues that we need to work on improving? 10:12 What does Bolt Biotherapeutics do, and what are their missions and initiatives? 12:26 What do you see happening with Bolt and this kind of technology and therapy over the next 5 to 10 years? 15:01 Jain and Perez discuss the evolution of precision oncology over the years 16:06 As a woman in this field, how did you navigate your path into these leadership roles? 19:17 If clinicians or trainees were interested in getting into the immuno-oncology industry space, how would you recommend they navigate a path? 22:04 Was the transition from industry to a smaller company scary, or did you know this is what you wanted to do next with your life? 24:06 Have you learned your leadership skills, or were they something you were taught? … Is the training more experience/on-the-job, or is it something you seek out? 26:03 If someone could only listen to the last 2 minutes of this episode, what would you want them to take away? 30:03 How to contact Perez 30:51 Thanks for listening 31:36 Edith A. Perez, M.D., is chief medical officer of Bolt Biotherapeutics and an internationally recognized translational researcher and cancer specialist. We'd love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow us on Twitter @HemOncToday and @ShikhaJainMD. Perez can be reached on LinkedIn or via email [email protected]. Disclosures: Jain reports no relevant financial disclosures. Perez reports employment with Bolt Biotherapeutics and Genentech, leadership at Bolt Biotherapeutics, stock and other ownership interests in Genentech/Roche, and a consulting or advisory role at Daiichi Sankyo, Puma Biotechnology, and Seattle Genetics.